ASCO 2018: Latest in bladder cancer treatments

Bookmark and Share
Published: 3 Jun 2018
Views: 4417
Prof Thomas Powles & Prof Shahrokh Shariat

Prof Thomas Powles (Barts Cancer institute, London) and Prof Shahrokh F. Shariat (Vienna General Hospital, Austria) meet at ASCO 2018 to discuss the current patient eligibility changes within immuno-oncology following new guidance from EMA/FDA and share their thoughts on emerging neoadjuvant data with checkpoint inhibitors following some investigator initiated trials.

Both experts share their views on recently presented data on IDO1 inhibitors and pan-FGFR kinase inhibitors and signpost that future management of urothelial cancers front line may involve combination of therapies of PDL-1 with PARP or CTLA-4 inhibitors.

Atezolizumab and pembrolizumab in platinum refractory bladder cancer
Prospects for CTLA4 and IDO combinations
FGFR inhibitors in clinical trials
Upcoming combinations for bladder cancer
Adjuvant and neoadjuvant therapies

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).